Search

Your search keyword '"Barone, Stefania"' showing total 133 results
Start Over Author "Barone, Stefania"
133 results on '"Barone, Stefania"'

5. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

Author

Zanghì, Aurora, Avolio, Carlo, Signoriello, Elisabetta, Abbadessa, Gianmarco, Cellerino, Maria, Ferraro, Diana, Messina, Christian, Barone, Stefania, Callari, Graziella, Tsantes, Elena, Sola, Patrizia, Valentino, Paola, Granella, Franco, Patti, Francesco, Lus, Giacomo, Bonavita, Simona, Inglese, Matilde, and D’Amico, Emanuele

Published
2022
Full Text
View/download PDF

7. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

Author

Zanghì, Aurora, Gallo, Antonio, Avolio, Carlo, Capuano, Rocco, Lucchini, Matteo, Petracca, Maria, Bonavita, Simona, Lanzillo, Roberta, Ferraro, Diana, Curti, Erica, Buccafusca, Maria, Callari, Graziella, Barone, Stefania, Pontillo, Giuseppe, Abbadessa, Gianmarco, Di Francescantonio, Valeria, Signoriello, Elisabetta, Lus, Giacomo, Sola, Patrizia, Granella, Franco, Valentino, Paola, Mirabella, Massimiliano, Patti, Francesco, and D’Amico, Emanuele

Published
2021
Full Text
View/download PDF

11. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

Author

Signori, Alessio, Saccà, Francesco, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Signoriello, Elisabetta, Repice, Anna Maria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Perini, Paola, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Pareja-Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barone, Stefania, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Landi, Doriana, Visconti, Andrea, and Sormani, Maria Pia

Published
2020
Full Text
View/download PDF

27. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

Author

Maniscalco, Giorgia T., primary, Saccà, Francesco, additional, Lanzillo, Roberta, additional, Annovazzi, Pietro, additional, Baroncini, Damiano, additional, Binello, Eleonora, additional, Repice, Annamaria, additional, Perini, Paola, additional, Clerico, Marinella, additional, Mataluni, Giorgia, additional, Bonavita, Simona, additional, La Gioia, Sara, additional, Gutierrez, Lorena Pareja, additional, Laroni, Alice, additional, Frau, Jessica, additional, Cocco, Eleonora, additional, Torri Clerici, Valentina, additional, Zarbo, Ignazio Roberto, additional, Sartori, Arianna, additional, Signoriello, Elisabetta, additional, Rasia, Sarah, additional, Cordioli, Cinzia, additional, Stromillo, Maria Laura, additional, Cerqua, Raffaella, additional, Pontecorvo, Simona, additional, Di Sapio, Alessia, additional, Grasso, Roberta, additional, Barone, Stefania, additional, Lavorgna, Luigi, additional, Barrilà, Caterina, additional, Landi, Doriana, additional, Russo, Cinzia Valeria, additional, Frigeni, Barbara, additional, Ippolito, Domenico, additional, Turano, Gabriella, additional, Carmisciano, Luca, additional, Sormani, Maria Pia, additional, and Signori, Alessio, additional

Published
2020
Full Text
View/download PDF

28. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

Author

Zecca, Chiara, primary, Bovis, Francesca, additional, Novi, Giovanni, additional, Capobianco, Marco, additional, Lanzillo, Roberta, additional, Frau, Jessica, additional, Repice, Anna Maria, additional, Hakiki, Bahia, additional, Realmuto, Sabrina, additional, Bonavita, Simona, additional, Curti, Erica, additional, Brambilla, Laura, additional, Mataluni, Giorgia, additional, Cavalla, Paola, additional, Di Sapio, Alessia, additional, Signoriello, Elisabetta, additional, Barone, Stefania, additional, Maniscalco, Giorgia T, additional, Maietta, Ilaria, additional, Maraffi, Isabella, additional, Boffa, Giacomo, additional, Malucchi, Simona, additional, Nozzolillo, Agostino, additional, Coghe, Giancarlo, additional, Mechi, Claudia, additional, Salemi, Giuseppe, additional, Gallo, Antonio, additional, Sacco, Rosaria, additional, Cellerino, Maria, additional, Malentacchi, Maria, additional, De Angelis, Marcello, additional, Lorefice, Lorena, additional, Magnani, Eliana, additional, Prestipino, Elio, additional, Sperli, Francesca, additional, Brescia Morra, Vincenzo, additional, Fenu, Giuseppe, additional, Barilaro, Alessandro, additional, Abbadessa, Gianmarco, additional, Signori, Alessio, additional, Granella, Franco, additional, Amato, Maria Pia, additional, Uccelli, Antonio, additional, Gobbi, Claudio, additional, and Sormani, Maria Pia, additional

Published
2019
Full Text
View/download PDF

29. MSJ872889_supplemental_table – Supplemental material for Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

Author

Zecca, Chiara, Bovis, Francesca, Novi, Giovanni, Capobianco, Marco, Lanzillo, Roberta, Frau, Jessica, Repice, Anna Maria, Hakiki, Bahia, Realmuto, Sabrina, Bonavita, Simona, Curti, Erica, Brambilla, Laura, Mataluni, Giorgia, Cavalla, Paola, Sapio, Alessia Di, Signoriello, Elisabetta, Barone, Stefania, Maniscalco, Giorgia T, Maietta, Ilaria, Maraffi, Isabella, Boffa, Giacomo, Malucchi, Simona, Nozzolillo, Agostino, Coghe, Giancarlo, Mechi, Claudia, Salemi, Giuseppe, Gallo, Antonio, Sacco, Rosaria, Cellerino, Maria, Malentacchi, Maria, Angelis, Marcello De, Lorefice, Lorena, Magnani, Eliana, Prestipino, Elio, Sperli, Francesca, Morra, Vincenzo Brescia, Fenu, Giuseppe, Barilaro, Alessandro, Abbadessa, Gianmarco, Signori, Alessio, Granella, Franco, Amato, Maria Pia, Uccelli, Antonio, Gobbi, Claudio, and Sormani, Maria Pia

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, MSJ872889_supplemental_table for Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience by Chiara Zecca, Francesca Bovis, Giovanni Novi, Marco Capobianco, Roberta Lanzillo, Jessica Frau, Anna Maria Repice, Bahia Hakiki, Sabrina Realmuto, Simona Bonavita, Erica Curti, Laura Brambilla, Giorgia Mataluni, Paola Cavalla, Alessia Di Sapio, Elisabetta Signoriello, Stefania Barone, Giorgia T Maniscalco, Ilaria Maietta, Isabella Maraffi, Giacomo Boffa, Simona Malucchi, Agostino Nozzolillo, Giancarlo Coghe, Claudia Mechi, Giuseppe Salemi, Antonio Gallo, Rosaria Sacco, Maria Cellerino, Maria Malentacchi, Marcello De Angelis, Lorena Lorefice, Eliana Magnani, Elio Prestipino, Francesca Sperli, Vincenzo Brescia Morra, Giuseppe Fenu, Alessandro Barilaro, Gianmarco Abbadessa, Alessio Signori, Franco Granella, Maria Pia Amato, Antonio Uccelli, Claudio Gobbi and Maria Pia Sormani in Multiple Sclerosis Journal

Published
2019
Full Text
View/download PDF

31. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience.

Author

Zecca, Chiara, Bovis, Francesca, Novi, Giovanni, Capobianco, Marco, Lanzillo, Roberta, Frau, Jessica, Repice, Anna Maria, Hakiki, Bahia, Realmuto, Sabrina, Bonavita, Simona, Curti, Erica, Brambilla, Laura, Mataluni, Giorgia, Cavalla, Paola, Di Sapio, Alessia, Signoriello, Elisabetta, Barone, Stefania, Maniscalco, Giorgia T, Maietta, Ilaria, and Maraffi, Isabella

Subjects
MULTIPLE sclerosis, B cells, MONOCLONAL antibodies, RITUXIMAB, JOHN Cunningham virus
Abstract

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). Objective: To investigate the effectiveness and safety of rituximab in relapsing–remitting (RR) and progressive MS. Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. Results: A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, p <.0001) and in secondary-progressive (SP) MS (from 0.34 to 0.06, p <.0001) and had a slight decrease in primary-progressive (PP) MS patients (from 0.12 to 0.07, p = 0.45). After 3 years from rituximab start, the proportion of patients with a confirmed EDSS progression was 14.6% in the RRMS group, 24.7% in the SPMS group, and 41.5% in the PPMS group. No major safety concerns arose. Conclusion: Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. Assessment of the Corticospinal Tract Profile in Pure Lower Motor Neuron Disease: A Diffusion Tensor Imaging Study.

Author

Sarica, Alessia, Valentino, Paola, Nisticò, Rita, Barone, Stefania, Pucci, Franco, Quattrone, Andrea, Cerasa, Antonio, and Quattrone, Aldo

Subjects
MOTOR neuron diseases, DIFFUSION tensor imaging, PYRAMIDAL tract, AMYOTROPHIC lateral sclerosis, DIAGNOSTIC imaging
Abstract

Aim: The aim of this study was to evaluate the corticospinal tract (CST) diffusion profile in pure lower motor neuron disease (pLMND) patients who at baseline did not show any clinical or electrophysiological involvement of upper motor neurons (UMN), and in amyotrophic lateral sclerosis (ALS) patients. Materials and Methods: Fifteen ALS patients with delayed central motor conduction time (CMCT) and 14 pLMND patients with normal CMCT were enrolled together with 15 healthy controls. Fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) maps were obtained. The tract profile of CST was reconstructed with the automated fiber quantification tool and its diffusion properties were quantified voxel-by-voxel and then compared pairwise between groups. Moreover, a random forest (RF) classifier was trained to evaluate the ability of CST diffusion metrics in distinguishing pairwise the groups from the controls. Results: ALS patients presented wide microstructural abnormalities in the entire CST as assessed by FA decrease and RD increase while pLMND patients showed focal FA decrease and a larger AD increase in the cerebral peduncle and posterior limb of the internal capsule in comparison with controls. RF revealed that diffusion tensor imaging (DTI) metrics accurately distinguished ALS patients and pLMND patients from controls (96.67 and 95.71% accuracy, respectively). Conclusions: Our study demonstrates that the CST was impaired in both ALS and pLMND patients, thus suggesting that DTI metrics are a reliable tool in detecting subtle changes of UMN in pLMND patients, also in the absence of clinical and CMCT abnormalities. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. Evaluation of machine learning algorithms performance for the prediction of early multiple sclerosis from resting-state FMRI connectivity data

Author

Saccà, Valeria, primary, Sarica, Alessia, additional, Novellino, Fabiana, additional, Barone, Stefania, additional, Tallarico, Tiziana, additional, Filippelli, Enrica, additional, Granata, Alfredo, additional, Chiriaco, Carmelina, additional, Bruno Bossio, Roberto, additional, Valentino, Paola, additional, and Quattrone, Aldo, additional

Published
2018
Full Text
View/download PDF

36. Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients

Author

Manna, Ida, primary, Iaccino, Enrico, additional, Dattilo, Vincenzo, additional, Barone, Stefania, additional, Vecchio, Eleonora, additional, Mimmi, Selena, additional, Filippelli, Enrica, additional, Demonte, Giulio, additional, Polidoro, Serena, additional, Granata, Alfredo, additional, Scannapieco, Sara, additional, Quinto, Ileana, additional, Valentino, Paola, additional, and Quattrone, Aldo, additional

Published
2018
Full Text
View/download PDF

37. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment

Author

Barone, Stefania, primary, Scannapieco, Sara, additional, Torti, Carlo, additional, Filippelli, Enrica, additional, Pisani, Vincenzo, additional, Granata, Alfredo, additional, Console, Domenico, additional, Demonte, Giulio, additional, Tallarico, Tiziana, additional, Polidoro, Serena, additional, Quattrone, Aldo, additional, and Valentino, Paola, additional

Published
2018
Full Text
View/download PDF

39. The corticospinal tract profile in amyotrophic lateral sclerosis

Author

Sarica, Alessia, Cerasa, Antonio, Valentino, Paola, Yeatman, Jason, Trotta, Maria, Barone, Stefania, Granata, Alfredo, Nisticò, Rita, Perrotta, Paolo, Pucci, Franco, and Quattrone, Aldo

Subjects
Adult, Male, Amyotrophic Lateral Sclerosis, Models, Neurological, Statistics as Topic, Pyramidal Tracts, Middle Aged, Nerve Fibers, Myelinated, Machine Learning, Disability Evaluation, Diffusion Tensor Imaging, Case-Control Studies, Image Processing, Computer-Assisted, Anisotropy, Humans, Female, Research Articles, Aged
Abstract

This work evaluates the potential in diagnostic application of a new advanced neuroimaging method, which delineates the profile of tissue properties along the corticospinal tract (CST) in amyotrophic lateral sclerosis (ALS), by means of diffusion tensor imaging (DTI). Twenty-four ALS patients and twenty-four demographically matched healthy subjects were enrolled in this study. The Automated Fiber Quantification (AFQ), a tool for the automatic reconstruction of white matter tract profiles, based on a deterministic tractography algorithm to automatically identify the CST and quantify its diffusion properties, was used. At a group level, the highest non-overlapping DTI-related differences were detected in the cerebral peduncle, posterior limb of the internal capsule, and primary motor cortex. Fractional anisotropy (FA) decrease and mean diffusivity (MD) and radial diffusivity (RD) increases were detected when comparing ALS patients to controls. The machine learning approach used to assess the clinical utility of this DTI tool revealed that, by combining all DTI metrics measured along tract between the cerebral peduncle and the corona radiata, a mean 5-fold cross validation accuracy of 80% was reached in discriminating ALS from controls. Our study provides a useful new neuroimaging tool to characterize ALS-related neurodegenerative processes by means of CST profile. We demonstrated that specific microstructural changes in the upper part of the brainstem might be considered as a valid biomarker. With further validations this method has the potential to be considered a promising step toward the diagnostic utility of DTI measures in ALS. Hum Brain Mapp 38:727-739, 2017. © 2016 Wiley Periodicals, Inc.

Published
2016

40. A survey of clinical features of allergic rhinitis in adults

Author

Frati, Franco, Dell’Albani, Ilaria, Passalacqua, Giovanni, Bonini, Sergio, Rossi, Oliviero, Senna, Gianenrico, Incorvaia, Cristoforo, Albano, Monica, Allegretti, Lucrezia, Altomonte, Giorgia, Antico, Andrea, Arena, ANTONIO IGNAZIO, Ariano, Renato, Arigliano, Pasquale, Arrigoni, Paola, Arsieni, Augusto, Aruanno, Arianna, Bernardis, Paola, Berra, Adriano, Billeri, Lucia, Boccafogli, Arrigo, Borghesan, Franco, Borgonovo, Linda, Borrelli, Paolo, Braga, Marina, Bresciani, Megan, Bruno, Guglielmo, Bruno, Massimo, Bruzzese, Domenico, Buonomo, Alessandro, Cadario, Gianni, Candi, Paolo, Cantone, Renato, Capretti, Stefania, Carabelli, Anna, Caramazza, Rino, Carbonara, Annamaria, Carosso, Aurelia, Caruso, Cristiano, Caruso, Riccardo, Casino, Giuseppe, Casotto, Stefano, Castellano, Francesco, Castiglioni, Gloria, Cecchi, Lidia, Chiarini, Francesca, Bianchi, Fulvia Chieco, Cinquepalmi, Giuseppe, Cinquini, Massimo, Cocchi, Silvia, Colangelo, Caterina, Colombo, Giselda, Cortellini, Gabriele, Crescioli, Stefano, Crimi, Nunzio, Cucinelli, Francesco, Curcio, Antonio, Cutajar, Marina, D’Amato, Gennaro, De Palma, Rafaele, Del Pozzo, Giuseppe, Torre, Fabrizio Della, Donne, Pantalea Delle, Di Claudio, Fabio, Di Leo, Elisabetta, Di Lorenzo, Gabriele, Di Marco, Giuseppe, Di Rocco Cesinaro, Paola, Distaso, Maria, Ditta, Vito, Emiliani, Francesca, Ermini, Giuseppe, Facchetti, Susanna, Farsi, Alessandro, Favero, Elisabetta, Folletti, Ilenia, Franchini, Maurizio, Gammeri, Enrico, Gangemi, Sebastiano, Gani, Federica, Gargano, Domenico, Giannoccaro, Francesco, Giro, Giuseppina, Gracefa, Dario, Greco, Giacomo, Guarnieri, Gabriella, Ingrassia, Antonino, Intravaia, Rossella, Iorno, Loredana, Piana, Simona La, Rosa, Luigi La, Laddaga, Rocco, Lamanna, Carlo, Landi, Massimo, Leonetti, Luigi, Barone, Stefania Leto, Liccardi, Gennaro, Lodi Rizzini, Fabio, Losappio, Laura, Lucivero, Giacomo, Macchia, Donatella, Madonna, Francesco, Mafezzoni, Enrico, Mancuso, Vincenzo, Manetti, Roberto, Manfredi, Giacomo, Manzoni, Silvia, Marcotulli, Maria, Marengo, Fulvia, D’Ippolito, Gianna Maria, Masieri, Simonetta, Matucci, Andrea, Mauro, Marina, Melchiorre, Antonietta, Menzella, Francesco, Micucci, Corrado, Mietta, Sabrina, Milanese, Manlio, Minetti, Stefano, Modiano, Ambra, Modica, Stella, Moinaghi, Marcello, Mondino, Michela, Munno, Giorgio, Muratore, Lionello, Murzilli, Francesco, Natoli, Rosalba, Nebiolo, Franco, Nettis, Eustachio, Olivieri, Elisa, Pannofno, Alessandro, Parpanesi, Mauro, Patella, Vincenzo, Petraroli, Angelica, Peveri, Silvia, Piantanida, Marta, Pietrafesa, Maria, Pinter, Elena, Pizzimenti, Stefano, Pompilio, Luana, Porcaro, Valeria, Prandini, Paolo, Pravettoni, Valerio, Pugliese, Salvatore, Quarta, Carlo, Quecchia, Cristina, Quercia, Oliviero, Quilleri, Roberto, Raie, Alberto, Randazzo, Salvatore, Ridolo, Erminia, Rolla, Giovanni, Romano, Antonino, Rota, Federica, Russello, Marina, Santucci, Annalisa, Savi, Eleonora, Scarantino, Giovanna, Scarpa, Sergio, Schiavino, Domenico, Sciacca, Angelo Rito, Serra, Paolo, Severino, Maurizio, Sirena, Alberto, Spadaro, Giuseppe, Spina, Francesca, Sugamiele, Mario, Taddeo, Giordano, Ventura, Maria Teresa, Testi, Sergio, Tombetti, Enrico, Tosoni, Cinzia, Triggiani, Massimo, Tripodi, Salvatore, Vallerani, Elisabetta, Vargiu, Arnoldo, Varricchio, Attilio, Zambito, Marcello, Zanforlin, Mario, Zanoni, Giovanna, Frati, F, Dell’Albani, I, Passalacqua, G, Bonini, Sergio, Rossi, O, Senna, G, Incorvaia, C, Adult SURF Study, Group, DE PALMA, Raffaele, Frati, Franco, Dell’Albani, Ilaria, Passalacqua, Giovanni, Rossi, Oliviero, Senna, Gianenrico, Incorvaia, Cristoforo, Albano, Monica, Allegretti, Lucrezia, Altomonte, Giorgia, Antico, Andrea, Arena, Antonio, Ariano, Renato, Arigliano, Pasquale, Arrigoni, Paola, Arsieni, Augusto, Aruanno, Arianna, Bernardis, Paola, Berra, Adriano, Billeri, Lucia, Boccafogli, Arrigo, Borghesan, Franco, Borgonovo, Linda, Borrelli, Paolo, Braga, Marina, Bresciani, Megan, Bruno, Guglielmo, Bruno, Massimo, Bruzzese, Domenico, Buonomo, Alessandro, Cadario, Gianni, Candi, Paolo, Cantone, Renato, Capretti, Stefania, Carabelli, Anna, Caramazza, Rino, Carbonara, Annamaria, Carosso, Aurelia, Caruso, Cristiano, Caruso, Riccardo, Casino, Giuseppe, Casotto, Stefano, Castellano, Francesco, Castiglioni, Gloria, Cecchi, Lidia, Chiarini, Francesca, Bianchi, Fulvia Chieco, Cinquepalmi, Giuseppe, Cinquini, Massimo, Cocchi, Silvia, Colangelo, Caterina, Colombo, Giselda, Cortellini, Gabriele, Crescioli, Stefano, Crimi, Nunzio, Cucinelli, Francesco, Curcio, Antonio, Cutajar, Marina, D’Amato, Gennaro, De Palma, Rafaele, Del Pozzo, Giuseppe, Torre, Fabrizio, Donne, Pantalea Delle, Di Claudio, Fabio, Di Leo, Elisabetta, Di Lorenzo, Gabriele, Di Marco, Giuseppe, Di Rocco Cesinaro, Paola, Distaso, Maria, Ditta, Vito, Emiliani, Francesca, Ermini, Giuseppe, Facchetti, Susanna, Farsi, Alessandro, Favero, Elisabetta, Folletti, Ilenia, Franchini, Maurizio, Gammeri, Enrico, Gangemi, Sebastiano, Gani, Federica, Gargano, Domenico, Giannoccaro, Francesco, Giro, Giuseppina, Gracefa, Dario, Greco, Giacomo, Guarnieri, Gabriella, Ingrassia, Antonino, Intravaia, Rossella, Iorno, Loredana, Piana, Simona La, Rosa, Luigi La, Laddaga, Rocco, Lamanna, Carlo, Landi, Massimo, Leonetti, Luigi, Barone, Stefania Leto, Liccardi, Gennaro, Lodi-Rizzini, Fabio, Losappio, Laura, Lucivero, Giacomo, Macchia, Donatella, Madonna, Francesco, Mafezzoni, Enrico, Mancuso, Vincenzo, Manetti, Roberto, Manfredi, Giacomo, Manzoni, Silvia, Marcotulli, Maria, Marengo, Fulvia, D’Ippolito, Gianna Maria, Masieri, Simonetta, Matucci, Andrea, Mauro, Marina, Melchiorre, Antonietta, Menzella, Francesco, Micucci, Corrado, Mietta, Sabrina, Milanese, Manlio, Minetti, Stefano, Modiano, Ambra, Modica, Stella, Moinaghi, Marcello, Mondino, Michela, Munno, Giorgio, Muratore, Lionello, Murzilli, Francesco, Natoli, Rosalba, Nebiolo, Franco, Nettis, Eustachio, Olivieri, Elisa, Pannofno, Alessandro, Parpanesi, Mauro, Patella, Vincenzo, Petraroli, Angelica, Peveri, Silvia, Piantanida, Marta, Pietrafesa, Maria, Pinter, Elena, Pizzimenti, Stefano, Pompilio, Luana, Porcaro, Valeria, Prandini, Paolo, Pravettoni, Valerio, Pugliese, Salvatore, Quarta, Carlo, Quecchia, Cristina, Quercia, Oliviero, Quilleri, Roberto, Raie, Alberto, Randazzo, Salvatore, Ridolo, Erminia, Rolla, Giovanni, Romano, Antonino, Rota, Federica, Russello, Marina, Santucci, Annalisa, Savi, Eleonora, Scarantino, Giovanna, Scarpa, Sergio, Schiavino, Domenico, Sciacca, Angelo Rito, Serra, Paolo, Severino, Maurizio, Sirena, Alberto, Spadaro, Giuseppe, Spina, Francesca, Sugamiele, Mario, Taddeo, Giordano, Ventura, Maria Teresa, Testi, Sergio, Tombetti, Enrico, Tosoni, Cinzia, Triggiani, Massimo, Tripodi, Salvatore, Vallerani, Elisabetta, Vargiu, Arnoldo, Varricchio, Attilio, Zambito, Marcello, Zanforlin, Mario, and Zanoni, Giovanna

Subjects
Adult, Male, medicine.medical_specialty, Allergen immunotherapy, Sublingual, Adolescent, medicine.medical_treatment, ARIA guidelines, Desensitization, allergic rhinitis, survey data, Drug treatment, Young Adult, Patient satisfaction, Allergic, Immunologic, Allergic Rhinitis, Internal medicine, Administration, Patient compliance, Rhinitis, Seasonal, Female, Humans, Italy, Middle Aged, Patient Satisfaction, Rhinitis, Allergic, Skin Tests, Treatment Outcome, Data Collection, Medicine (all), medicine, In patient, Young adult, Rhiniti, Desensitization (medicine), High prevalence, Skin Test, Adult patients, business.industry, Settore MED/09 - MEDICINA INTERNA, General Medicine, Surgery, Public Health, business, Human
Abstract

Background: Allergic rhinitis (AR) has high prevalence and substantial socio-economic burden.Material/Methods: The study included 35 Italian Centers recruiting an overall number of 3383 adult patients with rhinitis (48% males, 52% females, mean age 29.1, range 18-45 years). For each patient, the attending physician had to fill in a standardized questionnaire, covering, in particular, some issues such as the ARIA classification of allergic rhinitis (AR), the results of skin prick test (SPT), the kind of treatment, the response to treatment, and the satisfaction with treatment.Results: Out of the 3383 patients with rhinitis, 2788 (82.4%) had AR: 311 (11.5%) had a mild intermittent, 229 (8.8%) a mild persistent, 636 (23.5%) a moderate-severe intermittent, and 1518 (56.1%) a moderate-severe persistent form. The most frequently used drugs were oral antihistamines (77.1%) and topical corticosteroids (60.8%). The response to treatment was judged as excellent in 12.2%, good in 41.3%, fair in 31.2%, poor in 14.5%, and very bad in 0.8% of subjects. The rate of treatment dissatisfaction was significantly higher in patients with moderate-to-severe AR than in patients with mild AR (p

Published
2014

41. Superior Cerebellar Peduncle Atrophy Predicts Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients with Cerebellar Symptoms: A DTI Study

Author

Nicoletti, Giuseppe, primary, Valentino, Paola, additional, Chiriaco, Carmelina, additional, Granata, Alfredo, additional, Barone, Stefania, additional, Filippelli, Enrica, additional, Caligiuri, Maria Eugenia, additional, Vescio, Basilio, additional, Sarica, Alessia, additional, and Quattrone, Aldo, additional

Published
2017
Full Text
View/download PDF

43. The corticospinal tract profile in amyotrophic lateral sclerosis

Author

Sarica, Alessia, primary, Cerasa, Antonio, additional, Valentino, Paola, additional, Yeatman, Jason, additional, Trotta, Maria, additional, Barone, Stefania, additional, Granata, Alfredo, additional, Nisticò, Rita, additional, Perrotta, Paolo, additional, Pucci, Franco, additional, and Quattrone, Aldo, additional

Published
2016
Full Text
View/download PDF

44. The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing–remitting multiple sclerosis

Author

Caligiuri, Maria Eugenia, primary, Barone, Stefania, additional, Cherubini, Andrea, additional, Augimeri, Antonio, additional, Chiriaco, Carmelina, additional, Trotta, Maria, additional, Granata, Alfredo, additional, Filippelli, Enrica, additional, Perrotta, Paolo, additional, Valentino, Paola, additional, and Quattrone, Aldo, additional

Published
2015
Full Text
View/download PDF

45. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

Author

Aurora Zanghì, Carlo Avolio, Elisabetta Signoriello, Gianmarco Abbadessa, Maria Cellerino, Diana Ferraro, Christian Messina, Stefania Barone, Graziella Callari, Elena Tsantes, Patrizia Sola, Paola Valentino, Franco Granella, Francesco Patti, Giacomo Lus, Simona Bonavita, Matilde Inglese, Emanuele D’Amico, Zanghì, Aurora, Avolio, Carlo, Signoriello, Elisabetta, Abbadessa, Gianmarco, Cellerino, Maria, Ferraro, Diana, Messina, Christian, Barone, Stefania, Callari, Graziella, Tsantes, Elena, Sola, Patrizia, Valentino, Paola, Granella, Franco, Patti, Francesco, Lus, Giacomo, Bonavita, Simona, Inglese, Matilde, and D'Amico, Emanuele

Subjects
Pharmacology, Multiple Sclerosis, Pandemic, COVID-19, Gadolinium, Extended interval dosing, Standard interval dosing, Cytidine Diphosphate, Immunologic Factor, Multiple Sclerosis, Relapsing-Remitting, Recurrence, Humans, Immunologic Factors, Pharmacology (medical), Disease activity, Ocrelizumab, Neurology (clinical), Pandemics, Sudden Infant Death, MRI, Human
Abstract

In the COVID-19 pandemic era, safety concerns have been raised regarding the risk of severe infection following administration of ocrelizumab (OCR), a B-cell-depleting therapy. We enrolled all relapsing remitting multiple sclerosis (RRMS) patients who received maintenance doses of OCR from January 2020 to June 2021. Data were extracted in December 2021. Standard interval dosing (SID) was defined as a regular maintenance interval of OCR infusion every 6 months, whereas extended interval dosing (EID) was defined as an OCR infusion delay of at least 4 weeks. Three infusions were considered in defining SID vs. EID (infusions A, B, and C). Infusion A was the last infusion before January 2020. The primary study outcome was a comparison of disease activity during the A-C interval, which was defined as either clinical (new relapses) or radiological (new lesions on T1-gadolinium or T2-weighted magnetic resonance imaging (MRI) sequences). Second, we aimed to assess confirmed disability progression (CDP). A total cohort of 278 patients (174 on SID and 104 on EID) was enrolled. Patients who received OCR on EID had a longer disease duration and a higher rate of vaccination against severe acute respiratory syndrome-coronavirus 2 (p

Published
2022

46. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

Author

Gianmarco Abbadessa, Carlo Avolio, Patrizia Sola, Franco Granella, Graziella Callari, Stefania Barone, Elisabetta Signoriello, Simona Bonavita, Francesco Patti, Aurora Zanghì, Maria Buccafusca, Valeria Di Francescantonio, Antonio Gallo, Rocco Capuano, Diana Ferraro, Roberta Lanzillo, Paola Valentino, Matteo Lucchini, Erica Curti, Giuseppe Pontillo, Massimiliano Mirabella, Emanuele D'Amico, Maria Petracca, Giacomo Lus, Zanghì, Aurora, Gallo, Antonio, Avolio, Carlo, Capuano, Rocco, Lucchini, Matteo, Petracca, Maria, Bonavita, Simona, Lanzillo, Roberta, Ferraro, Diana, Curti, Erica, Buccafusca, Maria, Callari, Graziella, Barone, Stefania, Pontillo, Giuseppe, Abbadessa, Gianmarco, Di Francescantonio, Valeria, Signoriello, Elisabetta, Lus, Giacomo, Sola, Patrizia, Granella, Franco, Valentino, Paola, Mirabella, Massimiliano, Patti, Francesco, D'Amico, Emanuele, Zanghi, A., Gallo, A., Avolio, C., Capuano, R., Lucchini, M., Petracca, M., Bonavita, S., Lanzillo, R., Ferraro, D., Curti, E., Buccafusca, M., Callari, G., Barone, S., Pontillo, G., Abbadessa, G., Di Francescantonio, V., Signoriello, E., Lus, G., Sola, P., Granella, F., Valentino, P., Mirabella, M., Patti, F., and D'Amico, E.

Subjects
0301 basic medicine, Male, Immunosuppressive Agent, 0302 clinical medicine, Natalizumab, Immunologic Factor, Risk Factors, Retrospective Studie, Pharmacology (medical), Prospective Studies, Disease activity, Ocrelizumab, Drug Substitution, Progressive multifocal leukoencephalopathy, Leukoencephalopathy, Progressive Multifocal, Settore MED/26 - NEUROLOGIA, Original Article, Rituximab, Female, Immunosuppressive Agents, medicine.drug, Human, Adult, medicine.medical_specialty, Adolescent, Lower risk, Antibodies, Monoclonal, Humanized, Cladribine, Exit strategy, Follow-Up Studie, 03 medical and health sciences, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Internal medicine, Post-hoc analysis, medicine, Humans, Immunologic Factors, Retrospective Studies, Pharmacology, Expanded Disability Status Scale, business.industry, Multiple sclerosis, Risk Factor, medicine.disease, Prospective Studie, 030104 developmental biology, Neurology (clinical), business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

The main aim of the study is to evaluate the efficacy and safety profile of ocrelizumab (OCR), rituximab (RTX), and cladribine (CLA), employed as natalizumab (NTZ) exit strategies in relapsing–remitting multiple sclerosis (RRMS) patients at high-risk for progressive multifocal leukoencephalopathy (PML). This is a multicentre, retrospective, real-world study on consecutive RRMS patients from eleven tertiary Italian MS centres, who switched from NTZ to OCR, RTX, and CLA from January 1st, 2019, to December 31st, 2019. The primary study outcomes were the annualized relapse rate (ARR) and magnetic resonance imaging (MRI) outcome. Treatment effects were estimated by the inverse probability treatment weighting (IPTW), based on propensity-score (PS) approach. Additional endpoint included confirmed disability progression (CDP) as measured by Expanded Disability Status Scale and adverse events (AEs). Patients satisfying predefined inclusion and exclusion criteria were 120; 64 switched to OCR, 36 to RTX, and 20 to CLA. Patients from the 3 groups did not show differences for baseline characteristics, also after post hoc analysis. The IPTW PS-adjusted models revealed that patients on OCR had a lower risk for ARR than patients on CLA (ExpBOCR0.485, CI 95% 0.264–0.893,p = 0.020). This result was confirmed also for 12-month MRI activity (ExpBOCR0.248 CI 95% 0.065–0.948,p = 0.042). No differences were found in other pairwise comparisons (OCR vs RTX and RTX vs CLA) for the investigated outcomes. AEs were similar among the 3 groups. Anti-CD20 drugs were revealed to be effective and safe options as NTZ exit strategies. All investigated DMTs showed a good safety profile.

Published
2021

47. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

Author

Domenico Ippolito, Sara La Gioia, Sabrina Esposito, Valentina Torri Clerici, Giorgia Teresa Maniscalco, Cinzia Cordioli, Lorena Pareja-Gutierrez, Elisabetta Signoriello, Cinzia Valeria Russo, Roberta Grasso, Doriana Landi, B. Frigeni, Andrea Visconti, Caterina Barrilà, Valeria Barcella, Raffaella Cerqua, Alice Laroni, Simona Bonavita, Stefania Barone, P. Perini, Sarah Rasia, Arianna Sartori, Maria Laura Stromillo, Roberta Lanzillo, Damiano Baroncini, Jessica Frau, Francesco Saccà, Luigi Lavorgna, Alessio Signori, Ignazio Roberto Zarbo, Giorgia Mataluni, Eleonora Cocco, Maria Pia Sormani, E Binello, Pietro Annovazzi, M Clerico, Simona Pontecorvo, Giuseppe Fenu, Alessia Di Sapio, Anna Maria Repice, Signori, A., Sacca, F., Lanzillo, R., Maniscalco, G. T., Signoriello, E., Repice, A. M., Annovazzi, P., Baroncini, D., Clerico, M., Binello, E., Cerqua, R., Mataluni, G., Perini, P., Bonavita, S., Lavorgna, L., Zarbo, I. R., Laroni, A., Pareja-Gutierrez, L., La Gioia, S., Frigeni, B., Barcella, V., Frau, J., Cocco, E., Fenu, G., Clerici, V. T., Sartori, A., Rasia, S., Cordioli, C., Stromillo, M. L., Di Sapio, A., Pontecorvo, S., Grasso, R., Barone, S., Barrila, C., Russo, C. V., Esposito, S., Ippolito, D., Landi, D., Visconti, A., Sormani, M. P., Signori, Alessio, Saccà, Francesco, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Signoriello, Elisabetta, Repice, Anna Maria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Perini, Paola, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Pareja-Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barone, Stefania, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Landi, Doriana, Visconti, Andrea, and Sormani, Maria Pia

Subjects
Adult, Male, medicine.medical_specialty, Databases, Factual, Datasets as Topic, Settore MED/26, Placebo, Severity of Illness Index, law.invention, Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Randomized controlled trial, law, Internal medicine, Outcome Assessment, Health Care, Severity of illness, medicine, Humans, Immunologic Factors, Multicenter Studies as Topic, Glatiramer acetate, Cladribine, Randomized Controlled Trials as Topic, Retrospective Studies, business.industry, Middle Aged, Fingolimod, Observational Studies as Topic, Neurology, Propensity score matching, Disease Progression, Female, Neurology (clinical), business, medicine.drug
Abstract

ObjectiveCladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was compared by matching RCT to observational data.MethodsData from the pivotal trial assessing cladribine tablets vs placebo (CLARITY) were propensity score matched to data from the Italian multicenter database i-MuST. This database included 3,150 patients diagnosed between 2010 and 2018 at 24 Italian MS centers who started a disease-modifying drug. The annualized relapse rate (ARR) over 2 years from treatment start and the 24-week confirmed disability progression were compared between patients treated with cladribine and other approved drugs (interferon, glatiramer acetate, fingolimod, natalizumab, and dimethyl fumarate), with comparisons with placebo as a reference. Treatment effects were estimated by the inverse probability weighting negative binomial regression model for ARR and Cox model for disability progression. The treatment effect has also been evaluated according to baseline disease activity.ResultsAll weighted baseline characteristics were well balanced between groups. All drugs tested had an effect vs placebo close to that detected in the RCT. Patients treated with cladribine had a significantly lower ARR compared with interferon (relapse ratio [RR] = 0.48; p < 0.001), glatiramer acetate (RR = 0.49; p < 0.001), and dimethyl fumarate (RR = 0.6; p = 0.001); a similar ARR to that with fingolimod (RR = 0.74; p = 0.24); and a significantly higher ARR than natalizumab (RR = 2.13; p = 0.014), confirming results obtained by indirect treatment comparisons from RCTs (network meta-analyses). The relative effect of cladribine tablets 10 mg (cumulative dose 3.5 mg/kg over 2 years) was higher in patients with high disease activity vs all treatments except fingolimod and natalizumab. Effects on disability progression were largely nonsignificant, probably due to lack of power for such analysis.ConclusionIn patients with RRMS, cladribine tablets showed lower ARR compared with matched patients who started interferon, glatiramer acetate, or dimethyl fumarate; was similar to fingolimod; and was higher than natalizumab. The beneficial effect of cladribine tablets was generally amplified in the subgroup of patients with high disease activity.Classification of evidenceThis study provides Class III evidence that for patients with RRMS, cladribine-treated patients had lower ARR compared with interferon, glatiramer acetate, or dimethyl fumarate; similar ARR compared with fingolimod; and higher ARR compared with natalizumab.

Published
2020

48. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

Author

Antonio Gallo, Gianmarco Abbadessa, Chiara Zecca, Giancarlo Coghe, Giuseppe Salemi, Antonio Uccelli, Marco Capobianco, Stefania Barone, Rosaria Sacco, Lorena Lorefice, Claudia Mechi, Giorgia Mataluni, Elio Prestipino, Jessica Frau, Claudio Gobbi, Alessandro Barilaro, Giorgia Teresa Maniscalco, Erica Curti, E. Magnani, Bahia Hakiki, Maria Malentacchi, Simona Bonavita, Alessia Di Sapio, Francesca Bovis, Maria Cellerino, Franco Granella, Roberta Lanzillo, Anna Maria Repice, Marcello De Angelis, Isabella Maraffi, Laura Brambilla, Giuseppe Fenu, Elisabetta Signoriello, Alessio Signori, Paola Cavalla, Maria Pia Sormani, Agostino Nozzolillo, Giacomo Boffa, Simona Malucchi, Maria Pia Amato, Giovanni Novi, Sabrina Realmuto, Francesca Sperli, Ilaria Maietta, Vincenzo Brescia Morra, Zecca, C., Bovis, F., Novi, G., Capobianco, M., Lanzillo, R., Frau, J., Repice, A. M., Hakiki, B., Realmuto, S., Bonavita, S., Curti, E., Brambilla, L., Mataluni, G., Cavalla, P., Di Sapio, A., Signoriello, E., Barone, S., Maniscalco, G. T., Maietta, I., Maraffi, I., Boffa, G., Malucchi, S., Nozzolillo, A., Coghe, G., Mechi, C., Salemi, G., Gallo, A., Sacco, R., Cellerino, M., Malentacchi, M., De Angelis, M., Lorefice, L., Magnani, E., Prestipino, E., Sperli, F., Brescia Morra, V., Fenu, G., Barilaro, A., Abbadessa, G., Signori, A., Granella, F., Amato, M. P., Uccelli, A., Gobbi, C., Sormani, M. P., Zecca, Chiara, Bovis, Francesca, Novi, Giovanni, Capobianco, Marco, Lanzillo, Roberta, Frau, Jessica, Repice, Anna Maria, Hakiki, Bahia, Realmuto, Sabrina, Bonavita, Simona, Curti, Erica, Brambilla, Laura, Mataluni, Giorgia, Cavalla, Paola, Di Sapio, Alessia, Signoriello, Elisabetta, Barone, Stefania, Maniscalco, Giorgia T, Maietta, Ilaria, Maraffi, Isabella, Boffa, Giacomo, Malucchi, Simona, Nozzolillo, Agostino, Coghe, Giancarlo, Mechi, Claudia, Salemi, Giuseppe, Gallo, Antonio, Sacco, Rosaria, Cellerino, Maria, Malentacchi, Maria, De Angelis, Marcello, Lorefice, Lorena, Magnani, Eliana, Prestipino, Elio, Sperli, Francesca, Brescia Morra, Vincenzo, Fenu, Giuseppe, Barilaro, Alessandro, Abbadessa, Gianmarco, Signori, Alessio, Granella, Franco, Amato, Maria Pia, Uccelli, Antonio, Gobbi, Claudio, and Sormani, Maria Pia

Subjects
Multiple Sclerosis, medicine.drug_class, Lymphocyte depletion, relapsing–remitting, Monoclonal antibody, Primary progressive, 03 medical and health sciences, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, real life, medicine, Humans, Immunologic Factors, 030212 general & internal medicine, Secondary progressive, Retrospective Studies, primary progressive, business.industry, Multiple sclerosis, Rituximab, multiple sclerosis, secondary progressive, Treatment options, medicine.disease, Neurology, Relapsing remitting, Italy, multiple sclerosi, Immunology, Settore MED/26 - Neurologia, Neurology (clinical), business, 030217 neurology & neurosurgery, Switzerland, medicine.drug
Abstract

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). Objective: To investigate the effectiveness and safety of rituximab in relapsing–remitting (RR) and progressive MS. Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. Results: A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, p Conclusion: Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.

Published
2020

49. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.

Author

Zecca C, Bovis F, Novi G, Capobianco M, Lanzillo R, Frau J, Repice AM, Hakiki B, Realmuto S, Bonavita S, Curti E, Brambilla L, Mataluni G, Cavalla P, Di Sapio A, Signoriello E, Barone S, Maniscalco GT, Maietta I, Maraffi I, Boffa G, Malucchi S, Nozzolillo A, Coghe G, Mechi C, Salemi G, Gallo A, Sacco R, Cellerino M, Malentacchi M, De Angelis M, Lorefice L, Magnani E, Prestipino E, Sperli F, Brescia Morra V, Fenu G, Barilaro A, Abbadessa G, Signori A, Granella F, Amato MP, Uccelli A, Gobbi C, and Sormani MP

Subjects
Humans, Immunologic Factors therapeutic use, Italy, Retrospective Studies, Rituximab adverse effects, Switzerland, Multiple Sclerosis drug therapy, Multiple Sclerosis, Relapsing-Remitting drug therapy
Abstract

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS)., Objective: To investigate the effectiveness and safety of rituximab in relapsing-remitting (RR) and progressive MS., Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed., Results: A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, p  < .0001) and in secondary-progressive (SP) MS (from 0.34 to 0.06, p  < .0001) and had a slight decrease in primary-progressive (PP) MS patients (from 0.12 to 0.07, p  = 0.45). After 3 years from rituximab start, the proportion of patients with a confirmed EDSS progression was 14.6% in the RRMS group, 24.7% in the SPMS group, and 41.5% in the PPMS group. No major safety concerns arose., Conclusion: Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.

Published
2020
Full Text
View/download PDF

50. Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?

Author

Mazzitelli M, Barone S, Greco G, Serapide F, Valentino P, Giancotti A, Costa C, Pisani V, Quirino A, Liberto MC, Matera G, Gambardella A, Trecarichi EM, and Torti C

Subjects
Adult, Alemtuzumab therapeutic use, Female, Humans, Multiple Sclerosis drug therapy, Alemtuzumab adverse effects, Listeriosis chemically induced
Abstract

Few cases of complicated infections with Listeria monocytogenes (LM) have been reported to date in patients with multiple sclerosis (MS) treated with alemtuzumab. Primary prevention strategies may be suggested in such patients to avoid infections. However, these may be ineffective because patients may already be carriers of LM. We report herein a case of bloodstream infection due to LM in a 25-year-old woman with MS treated with alemtuzumab. We searched the UMC/WHO Vigibase system for all reported cases of LM in patients treated with alemtuzumab and found 29 cases overall up to 21 July 2019. We also performed a literature review of MS cases with LM on alemtuzumab, in order to evaluate epidemiology, clinical characteristics, and outcome of this complication. Since the published cases (N=8) were mainly reported in recent years but more cases were found in the UMC/WHO Vigibase system (although not necessarily in patients with MS), we hypothesize that this complication is more frequent than currently believed and may become even more important in the future. Therefore, it is worth reaching a consensus on appropriate algorithms to stratify individuals by risk so as to implement targeted prevention strategies (whether primary or secondary).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results